Ụlọ ọrụ mmepụta ihe 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7

Iji mezuo afọ ojuju nke ndị ahịa 'n'elu-atụ anya, anyị nwere ugbu a anyị ike ndị ọrụ na-enye anyị kasị ukwuu n'ozuzu enyemaka nke incorporates akwalite, nnukwu ahịa, atụmatụ, e kere eke, top àgwà njikwa, mbukota, nkwakọba ihe na lọjistik maka Factory Supply 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Anyị nwere ezi obi na-emeghe.Anyị na-atụ anya nleta gị na ịmepụta mmekọrịta ntụkwasị obi na ogologo oge.
Iji mezuo afọ ojuju nke ndị ahịa, anyị nwere ugbu a, ndị ọrụ ụgbọ mmiri anyị siri ike na-enye enyemaka n'ozuzu anyị kachasị ukwuu nke gụnyere nkwalite, oke ahịa, atụmatụ, okike, njikwa mma, mbukọ, nkwakọba ihe na ngwa agha makaChina CAS 112704-79-7 na 112704-79-7, Ngwaahịa anyị enwetala aha ọma na mba ọ bụla metụtara ya.N'ihi na oruru nke ụlọ ọrụ anyị.anyị siri ọnwụ na usoro mmepụta anyị ọhụrụ yana usoro njikwa ụbọchị kachasị ọhụrụ, na-adọta nnukwu talent n'ime ụlọ ọrụ a.Anyị na-ewere ngwọta dị mma dị ka àgwà kacha mkpa anyị.

A na-eji 1-Bromo-2-methoxy-3-nitro-benzene mee ihe dị ka etiti Eltrombopag.
Eltrombopag, nke GlaxoSmithKline (GSK) mepụtara na UK ma mechaa mebere ya na Novartis na Switzerland, bụ nke mbụ na naanị akwadoro obere molecule na-abụghị peptide TPO agonist n'ụwa.Ndị US FDA kwadoro Eltrombopag na 2008 maka ọgwụgwọ nke idiopathic thrombocytopenic purpura (ITP), na 2014 maka ọgwụgwọ nke anaemia siri ike (AA).Ọ bụkwa ọgwụ izizi nke US FDA kwadoro maka ọgwụgwọ AA n'ime afọ 30 na-adịbeghị anya.
Na december2012, US FDA kwadoro Eltrombopag maka ọgwụgwọ thrombocytopenia na-arịa ọrịa ịba ọcha n'anya C (CHC), nke mere na ndị ọrịa ịba ọcha n'anya C na-arịa ọrịa na-adịghị mma n'ihi ọnụ ọgụgụ platelet dị ala nwere ike ịmalite ma nọgide na-enwe usoro ọgwụgwọ interferon dabeere na ọgwụgwọ maka ọrịa imeju.Na Febụwarị 3,2014, GlaxoSmithKline kwupụtara na FDA nyere ntozu ọgwụgwọ ọgwụgwọ ọgwụgwọ Eltrombopag maka ọgwụgwọ hemopenia na ndị ọrịa nwere nnukwu akwụkwọ kemịkal aplastic anaemia (SAA) bụ ndị na-anabataghị nke ọma na immunotherapy.Na August 24, 2015, US FDA kwadoro Eltrombopag maka ọgwụgwọ thrombocytopenia na ndị okenye na ụmụaka dị afọ 1 na karịa na-adịghị ala ala thrombocytopenia (ITP) ndị na-enweghị nzaghachi zuru oke na corticosteroids, immunoglobulins ma ọ bụ splenectomy.Na Jenụwarị 4, 2018, a kwadoro Eltrombopag ka edepụta ya na China maka ọgwụgwọ nke thrombocytopenia nke mbụ na-alụso ọrịa ọgụ (ITP).

Iji mezuo afọ ojuju nke ndị ahịa 'n'elu-atụ anya, anyị nwere ugbu a anyị ike ndị ọrụ na-enye anyị kasị ukwuu n'ozuzu enyemaka nke incorporates akwalite, nnukwu ahịa, atụmatụ, e kere eke, top àgwà njikwa, mbukota, nkwakọba ihe na lọjistik maka Factory Supply 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Anyị nwere ezi obi na-emeghe.Anyị na-atụ anya nleta gị na ịmepụta mmekọrịta ntụkwasị obi na ogologo oge.
Nkwanye ụlọ ọrụChina CAS 112704-79-7 na 112704-79-7, Ngwaahịa anyị enwetala aha ọma na mba ọ bụla metụtara ya.N'ihi na oruru nke ụlọ ọrụ anyị.anyị siri ọnwụ na usoro mmepụta anyị ọhụrụ yana usoro njikwa ụbọchị kachasị ọhụrụ, na-adọta nnukwu talent n'ime ụlọ ọrụ a.Anyị na-ewere ngwọta dị mma dị ka àgwà kacha mkpa anyị.